Physician
Bayshore Pathology Consultants PA
Bayshore Pathology Consultants PA was paid $318K by Medicaid between May 2020 and Nov 2024, across 14 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 21% of everything it billed.
33Billing provider infoBAYSHORE PATHOLOGY CONSULTANTS PA
PORT CHARLOTTE, FL 33948
PORT CHARLOTTE, FL 33948
33aNPI1700217460assigned 12/06/2013
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$318K
24GClaims13,942
24DCodes billed14
24AFirst – last monthMay 2020 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Florida
Rank by total paid#39 of 207
Median peer was paid$39K
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 497 | $8K | |
| 2021 | 1,006 | $22K | |
| 2022 | 8,191 | $198K | |
| 2023 | 3,348 | $82K | |
| 2024incomplete | 900 | $8K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 21% | 1,576 | 1,351 | $66K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 12% | 1,791 | 1,737 | $37K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 11% | 1,880 | 1,808 | $36K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 11% | 2,011 | 1,939 | $34K |
| 87481 | 7.9% | 1,011 | 574 | $25K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 7.6% | 774 | 743 | $24K |
| 88141 | 7.3% | 1,154 | 1,106 | $23K | |
| 87625 | 6.9% | 1,039 | 953 | $22K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 6.7% | 1,192 | 1,105 | $21K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 5.3% | 992 | 954 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 388 | 255 | $8K |
| 88312 | 1.1% | 53 | 50 | $3K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialOQUENDO, VIRGINIA (CREDENTIALING SPECIALIST)